Pharmacogenetics of anti-HIV drugs

Annual Review of Pharmacology and Toxicology

Volumn 48, Issue , 2008, Pages 227-256

  Telenti, A ^a   Zanger, U M ^b,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

ADME proteins; HIV susceptibility; Non nucleoside reverse transcriptase inhibitors; Nucleoside analogue reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ABACAVIR; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; CELL NUCLEUS RECEPTOR; COTRIMOXAZOLE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; DIDANOSINE; DIMETHYLANILINE MONOOXYGENASE; EFAVIRENZ; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; RITONAVIR; SAQUINAVIR; SULFOTRANSFERASE; TENOFOVIR; ZIDOVUDINE;

ABCB1 GENE; ALLELE; ALPHA 1 ACID GLYCOPROTEIN GENE; AREA UNDER THE CURVE; BIOTRANSFORMATION; CD4+ T LYMPHOCYTE; CYP2B6 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP3AS GENE; DISEASE COURSE; DISEASE PREDISPOSITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRESS SYNDROME; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; EFFUSION; FEVER; GENE; GENE CLUSTER; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; HAPLOTYPE; HAPLOTYPE MAP; HEPATITIS; HEREDITY; HUMAN; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; MDR1 GENE; MRP2 GENE; MRP4 GENE; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICOGENETICS; ANIMAL; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANIMALS; ANTI-HIV AGENTS; DISEASE PROGRESSION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 41149119612     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.48.113006.094753     Document Type: Review

References (163)

1. Fellay J, Boubaker K, Ledergerber B, Furrer H, Battegay M, et al. 2001. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 58:1322-27
2. Syvanen AC. 2005. Toward genome-wide SNP genotyping. Nat. Genet. 37(Suppl.):S5-10
3. Telenti A, Goldstein DB. 2006. Genomics meets HIV. Nat. Rev. Microbiol. 4:9-18
4. Roses AD. 2004. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet. 5:645-56
5. Telenti A, Egger M. 2007. Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors. Antivir. Ther. 2:147-48
6. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. 2006. Biology of CCR5 and its role in HIV infection and treatment. JAMA 296:815-26
7. Rotger M, Csajka C, Telenti A. 2006. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr. HIV/AIDS Rep. 3:118-25
8. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. 2002. Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther. 40:507-19
9. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, et al. 2003. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. 47:130-37
10. Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, et al. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73:20-30
11. Anderson PL, Kakuda TN, Lichtenstein KA. 2004. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743-53
12. Meyer UA. 2000. Pharmacogenetics and adverse drug reactions. Lancet 356:1667-71
13. Zanger UM, Raimundo S, Eichelbaum M. 2004. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369:23-37
14. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. 2001. Analysis of variation in plasma concentrations of nelfinavir and its active metaholite M8 in HIV-positive patients. AIDS 15:991-98
15. Haas DW, Smeaton LM, Shafer RW, Rohbins GK,Morse GD, et al. 2005. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192:1931-42
16. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, et al. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36
17. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, et al. 2005. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS 19:371-80
18. Burger DM, Schwietert HR, Colbers EP, Becker M. 2006. The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir. Br. J Clin Pharmacol 62:250-52
19. Burk O, Wojnowski L. 2004. Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch. Pharmacol. 369:105-24
20. Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, et al. 2003. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-88
21. Daly AK. 2006. Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 45:13-31
22. He P, Court MH, Greenblatt DJ, von Moltke LL. 2005. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther. 77:373-87
23. Zeigler-Johnson C, Friebel T, Walker AH, Wang Y, Spangler E, et al. 2004. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64:8461-67
24. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, et al. 2004. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18:2391-400
25. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306:287-300
26. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, et al. 2004. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319:1322-26
27. Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, et al. 2006. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics 16:837-45
28. Frohlich M, Hoffmann MM, Burhenne J, Mikus G, Weiss J, Haefeli WE. 2004. Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br. J. Clin. Pharmacol. 58:443-44
29. Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, et al. 2005. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther. 78:605-18
30. Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, et al. 2007. CYP3A5 Genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81:708-12
31. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. 2006. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune. Defic. Syndr. 42:441-49
32. Ernest CS, Hall SD, Jones DR. 2005. Mechanism-based inactivation of CYP3A hy HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312:583-91
33. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, et al. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415
34. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, et al. 2003. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307:906-22
35. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, et al. 2004. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14:225-38
36. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, et al. 2005. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15:861-73
37. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, et al. 2005. A natural CYP2B6 TATA box polymorphism (-82T-> C) leading to enhanced transcription and relocation of the transcriptional start site. Mol. Pharmacol. 67:1772-82
38. Desta Z, Saussele T, Ward BA, Blievernicht J, Li L, et al. 2007. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8(No. 6):547-58
39. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, et al. 2007. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81:557-66
40. Lang T, Klein K, Richter T, Zibat A, Kerb R, et al. 2004. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther. 311:34-43
41. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, et al. 2006. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics 16:191-98
42. Marzolini C, Telenti A, Decosterd L, Biollaz J, Buclin T. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:1193-94
43. Langmann P, Weissbrich B, Desch S, Väth T, Schirmer D, et al. 2002. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur. J. Med. Res. 7:309-14
44. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, et al. 2005. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet, Genomics 15:1-5
45. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. 2005. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40:1358-61
46. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. 2003. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122-32
47. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, et al. 2006. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study. Clin. Infect. Dis. 42:401-7
48. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, et al. 2007. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8:86-91
49. Blievernicht JK, Schaeffeler E, Klein K, Eichelbaum M, Schwab M, Zanger UM. 2007. MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms. Clin. Chem. 53:24-33
50. Mehlotra RK, Bockarie MJ, Zimmerman PA. 2007. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br. J. Clin. Pharmacol. In press
51. Rotger M, Saumoy M, Zhang K, Flepp M, Sahli R, et al. 2007. Partial deletion of CYP2B6 due to unequal crossover with CYP2B7. Pharmacogenet. Genomics. In press
52. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, et al. 2003. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-26
53. Geick A, Eichelbaum M, Burk O. 2001. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276:14581-87
54. Marzolini C, Tirona RG, Kim RB. 2005. Pharmacogenomics of drug transporters. In Pharmacogenomics, ed. W Kalow, UA Meyer, RF Tyndale, pp. 109-56. Oxford, UK: Taylor & Francis Books
55. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA 84:7735-38
56. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 86:695-98
57. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. 1994. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451-58
58. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
59. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, et al. 1999. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab. Dispos. 27:581-87
60. Marzolini C, Paus E, Buclin T, Kim RB. 2004. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75:13-33
61. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, et al. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-78
62. Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T, et al. 2004. Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir. Ther. 9:929-35
63. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, et al. 2005. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics 15:599-608
64. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, et al. 2003. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8:531-34
65. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JSG, et al. 2003. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17:201-8
66. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, et al. 2003. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an Adult AIDS Clinical Trials Group study. J. Acquir. Immune Defic. Syndr. 34:295-98
67. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, et al. 2003. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 17:1696-98
68. Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, et al. 2005. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS 19:2127-31
69. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. 2007. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-28
70. Komar AA. 2007. Genetics, SNPs, silent but not invisible. Science 315:466-67
71. Akiyama TE, Gonzalez FJ. 2003. Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim. Biophys. Acta 1619:223-34
72. Timsit YE, Negishi M. 2007. CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231-46
73. Handschin C, Meyer UA. 2003. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55:649-73
74. Lim YP, Huang JD. 2007. Pregnane X receptor polymorphism affects CYP3A4 induction via a ligand-dependent interaction with steroid receptor coactivator-1. Pharmacogenet. Genomics 17:369-82
75. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. 2001. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276:33309-12
76. Faucette SR, Sueyoshi T, Smith CM, Negishi M, LeCluyse EL, Wang H. 2006. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317:1200-9
77. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski C, et al. 2007. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther. 320:72-80
78. Lamba J, Lamba V, Schuetz E. 2005. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab. 6:369-83
79. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. 2001. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29:1454-59
80. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, et al. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-72
81. Lubomirov R, Csajka C, Telenti A. 2007. An ADME pathway approach for pharmacogenetic studies of anti-HIV therapy. Pharmacogenomics 8:623-33
82. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. 2005. A haplotype map of the human genome. Nature 437:1299-320
83. Goldstein DB, Cavalleri GL. 2005. Genomics: understanding human diversity. Nature 437:1241-42
84. Ahmadi KR, Weale ME, Xue ZY, Soranzo N, Yarnall DP, et al. 2005. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat. Genet. 37:84-89
85. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, et al. 2006. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 34:W635-41
86. Hemminger BM, Saelim B, Sullivan PF. 2006. TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits. Bioinformatics 22:626-27
87. Zanni MP, von Greyerz S, Schnyder B, Brander KA, Frutig K, et al. 1998. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J. Clin. Invest. 102:1591-98
88. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S, Naisbitt DJ, et al. 2000. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 164:6647-54
89. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. 2001. Metabolic activation in drug allergies. Toxicology 158:11-23
90. Hewitt RG. 2002. Abacavir hypersensitivity reaction. Clin. Infect. Dis. 34:1137-42
91. Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. 2001. Hypersensitivity related to abacavir in two members of a family. Ann. Pharmacother. 35:1291-92
92. Mallal S, Nolan D, Witt C, Masel G, Martin AM, et al. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-32
93. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, et al. 2002. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121-22
94. Nolan D, Gaudieri S, Mallal S. 2003. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J. HIV Ther. 8:36-41
95. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. 2004. Cost-effectiveness analysis of HLA B* 5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14:335-42
96. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, et al. 2004. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5:203-11
97. Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D, CNA106030 Study Team. 2007. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm. Stat. In press
98. Lucas A, Nolan D, Mallal S. 2007. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J. Antimicrob. Chemother. 59:591-93
99. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. 2003. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1):S21-33
100. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. 2004. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 35:120-s5
101. Martin AM, Nolan D, James I, Cameron P, Keller J, et al. 2005. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19:97-99
102. Littera R, Carcassi C, Masala A, Piano P, Serra P, et al. 2006. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20:1621-26
103. Gatanaga H, Yazaki H, Tanuma J, Honda M, Genka I, et al. 2007. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21:264-65
104. Behrens G, Schmidt HH, Stoll M, Schmidt RE. 1999. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet 354:76
105. Fauvel J, Bonnet E, Ruidavets JB, Fernères J, Toffoletti A, et al. 2001. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15:2397-406
106. Tarr PE, Taffe P, Bleiber G, Furrer H, Rotger M, et al. 2005. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 191:1419-26
107. Arnedo M, Taffé P, Sahli R, Furrer H, Hirschel B, et al. 2007. Evaluation of the contribution of 20 variants of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics. 7:755-64
108. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, et al. 2003. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17:121-23
109. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. 2002. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16:2013-18
110. Wallace KB, Starkov AA. 2000. Mitochondrial targets of drug toxicity. Annu. Rev. Pharmacol. Toxicol. 40:353-88
111. Luzhansky JZ, Pierce AB, Hoy JF, Hall AJ. 2001. Leber's hereditary optic neuropathy in the setting of nucleoside analogue toxicity. AIDS 15:1588-89
112. Shaikh S, Ta C, Basham AA, Mansour S. 2001. Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection. Am. J. Ophthalmol. 131:143-45
113. Warner JE, Ries KM. 2001. Optic neuropathy in a patient with AIDS. J. Neuroophthalmol. 21:92-94
114. Mackey DA, Fingert JH, Luzhansky JZ, McCluskey PJ, Howell N, et al. 2003. Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus. Eye 17:312-17
115. Hulgan T, Haas DW, Haines JL, Ritchie MD, Robbins GK, et al. 2005. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an Adult AIDS Clinical Trials Group study. AIDS 19:1341-49
116. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, et al. 2004. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429:417-23
117. Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, et al. 2004. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 18:1291-97
118. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:725-33
119. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. 2003. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem. J. 371:897-905
120. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. 2001. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276:9626-30
121. Konig J, Cui Y, Nies AT, Keppler D. 2000. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278:G156-64
122. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40:581-616
123. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, et al. 1995. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333:1171-75
124. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. 1996. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347:578-81
125. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. USA 98:12671-76
126. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, et al. 2005. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192:1381-86
127. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. 2005. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15:513-22
128. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. 2005. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33:434-39
129. Tirona RG, Lcake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276:35669-75
130. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. 2004. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75:415-21
131. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, et al. 2004. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B11). Pharmacogenetics 14:429-40
132. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, et al. 2005. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77:468-78
133. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. 2005. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 59:602-4
134. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, et al. 2003. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73:554-65
135. Rotger M, Taffe P, Bleiber G, Günthard HF, Furrer H, et al. 2005. Contribution of genetic polymorphisms in UGT1A1 and SCLO1B1 to the developmetit of antiretroviral therapy assocîated hyperbilirubinemia. Int. Conf. Antimicrob. Agents and Chemother., 45th, Washington, DC (Abstr.)
136. Adkins JC, Noble S. 1998. Efavirenz. Drugs 56:1055-64
137. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J. 2003. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 4:62-66
138. Dassopoulos T, Ehrenpreis ED. 1999. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am. J. Med. 107:78-84
139. Sharer N, Schwarz M, Malone G, Howarth A, Painter J, et al. 1998. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N. Engl. J. Med. 339:645-52
140. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. 1998. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N. Engl. J. Med. 339:653-58
141. Pfutzer RH, Barmada MM, Brunskill AP, Finch R, Hart PS, et al. 2000. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology 119:615-23
142. Frossard JL, Morris MA, Wonkam A, Hirschel B, Flepp M, et al. 2004. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case control study. AIDS 18:1521-27
143. Telenti A, Bleiber G. 2006. Host genetics of HIV-1 susceptibility. Future Virol. 1:55-70
144. Carrington M, Nelson G, O'Brien SJ. 2001. Considering genetic profiles in functional studies of immune responsiveness to HIV-1. Immunol. Lett. 79:131-40
145. Carrington M, O'Brien SJ. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-51
146. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31:429-34
147. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856-62
148. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. 1996. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-25
149. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-43
150. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, et al. 1999. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc. Natl. Acad. Sci. USA 96:12004-9
151. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, et al. 1998. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat. Med. 4:786-93
152. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, et al. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277:959-65
153. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-40
154. Bashirova AA, Bleiber G, Qi Y, Hutcheson H, Yamashita T, et al. 2006. Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1. J. Virol. 80:6757-63
155. Bleiber G, May M, Martinez R, Meylan P, Ott J, et al. 2005. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J. Virol. 79:12674-80
156. Telenti A. 2006. Host polymorphism in postentry steps of the HIV-1 life cycle and other genetic variants influencing HIV-1 pathogenesis. Curr. Opin. HIV/AIDS 1:232-40
157. O'Brien SJ, Nelson GW. 2004. Human genes that limit AIDS. Nat. Genet. 36:565-74
158. Nelson GW, O'Brien SJ. 2006. Using mutual information to measure the impact of multiple genetic factors on AIDS. J. Acquir. Immune Defic. Syndr. 42:347-54
159. Fellay K, Shianna KV, Ge D, Colombo S, Ledergerber B, Weak M, et al. 2007. Identification of major determinants of the host control of HIV-1 through a whole-genome association study Science 317:944-47
160. Evans DM, Cardon LR. 2006. Genome-wide association: a promising start to a long race. Trends Genet. 22:350-54
161. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al. 2007. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881-85
162. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. 2006. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314:1461-63
163. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al. 2007. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-64